56,868 Shares in IQVIA Holdings Inc. $IQV Acquired by Nykredit A S

Nykredit A S acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 56,868 shares of the medical research company’s stock, valued at approximately $10,988,000.

Several other hedge funds have also recently made changes to their positions in IQV. Apella Capital LLC grew its stake in IQVIA by 5.1% during the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after purchasing an additional 58 shares during the last quarter. Quadrant Capital Group LLC boosted its position in IQVIA by 1.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after buying an additional 60 shares during the last quarter. Private Advisor Group LLC increased its holdings in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the period. Breakwater Capital Group raised its position in IQVIA by 3.2% during the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after buying an additional 64 shares during the last quarter. Finally, First Growth Capital LLC lifted its stake in IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 68 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Down 1.6%

IQV stock opened at $267.34 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a 50-day moving average of $230.54 and a two-hundred day moving average of $192.66. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $271.80. The company has a market cap of $44.00 billion, a price-to-earnings ratio of 33.17, a PEG ratio of 2.29 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period in the prior year, the business earned $2.81 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. Barclays reissued an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Robert W. Baird lifted their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, JPMorgan Chase & Co. upped their price target on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.62.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.